新型抗CD123嵌合抗原受体T细胞的构建及其抗急性髓系白血病效应
通过杂交瘤技术获得稳定分泌抗人CD123单克隆抗体的6E11细胞株,以其可变区序列构建CD123 CAR慢病毒载体并制备6E11 CAR-T细胞;体外实验显示6E11 CAR-T对CD123阳性AML细胞系及原代AML细胞具有特异性杀伤和激活能力,对CD123阴性细胞无明显作用。
要点
- 6E11单克隆抗体对CD123蛋白亲和性高,Kd值为2.10 nmol/L,特异性识别CD123阳性细胞。
- 6E11 CAR-T细胞感染效率大于60%,对CD123阳性MV4-11细胞杀伤率(98.60±1.20)%高于对照(20.28±6.74)%(P<0.001)。
- 6E11 CAR-T可被CD123阳性AML原代细胞激活并有效杀伤,对CD123阴性K562细胞无明显杀伤。
核心结论
- 6E11杂交瘤细胞株能稳定分泌高效特异的抗人CD123单克隆抗体,可用于检测人CD123表达及靶向人CD123蛋白的肿瘤免疫治疗。
- 以6E11 Ig可变区序列为抗原识别区的CD123 CAR-T细胞具有明确的体外抗白血病活性,为进一步的临床研究奠定了基础。
研究设计与样本
- 实验研究:通过单克隆筛选技术获得稳定分泌CD123抗体的杂交瘤细胞株6E11,扩增后腹腔注射至Balb/c小鼠收集腹水纯化单克隆抗体。
- RT-PCR法获得轻链和重链可变区序列,利用分子克隆技术构建靶向CD123嵌合抗原受体,包装病毒感染T细胞制备6E11 CAR-T细胞。
- 通过共培养实验、脱颗粒实验和细胞因子释放实验评估6E11 CAR-T细胞体外抗CD123阳性AML细胞系及原代AML细胞的能力。
主要发现
- 获得1株稳定分泌抗人CD123抗体的杂交瘤细胞株6E11并获得其可变区序列,6E11单克隆抗体Kd值为2.10 nmol/L。
- 6E11单克隆抗体特异性识别CD123阳性细胞系THP-1,与CD123阴性细胞系Jurkat无交叉反应。
- 感染效率大于60%;效靶比1∶1时6E11 CAR-T对MV4-11细胞杀伤比例(98.60±1.20)%高于Vector-T细胞(20.28±6.74)%(P<0.001),对K562细胞无明显杀伤。
- MV4-11细胞激活6E11 CAR-T比例(26.33±3.30)%高于Vector-T细胞(1.17±0.06)%(P<0.001)。
- 与MV4-11共培养时6E11 CAR-T组IL-2(92.90±1.51)pg/ml、TNF-α(1 407.20±91.95)pg/ml、IFN-γ(5 614.60±170.17)pg/ml均高于Vector-T组(分别为6.05±3.41、7.86±0.85、8.42±2.70 pg/ml)(P<0.001);与K562共培养后两组各细胞因子水平差异无统计学意义。
临床怎么用
- 6E11杂交瘤细胞株分泌的抗人CD123单克隆抗体可用于检测表达人CD123的细胞。
- 作者认为6E11单克隆抗体也能应用在靶向人CD123蛋白的肿瘤免疫治疗中。
- 作者认为以6E11 Ig可变区序列为抗原识别区的CD123 CAR-T细胞具有明确的体外抗白血病活性,为进一步的临床研究奠定了基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To construct a new CD123- specific chimeric antigen receptor in order to provide a foundation for immunotherapy of CD123 positive leukemia. Methods: A hybridoma strain (6E11) capable of stably secreting CD123 antibody was obtained by a monoclonal screening technique, and the hybridoma cells were expanded and injected intraperitoneally to the pretreated Balb/c mice. Ascites was collected and purified to obtain the monoclonal antibody (mAb) . The affinity and specificity of 6E11 mAb were measured. The variable regions of the heavy and light chains of the 6E11 mAb were cloned by RT-PCR from the 6E11 mouse hybridoma. We generated a new CD123 specific chimeric antigen receptor with a scFv fragment derived from 6E11 antibody, designated as 6E11 CAR. T cells were transduced with lentiviral supernatant from 293T cells transfected with 6E11 CAR plasmid to generate 6E11 CAR-T cells. The specific cytotoxicity of 6E11 CAR-T against CD123(+) acute myeloid leukemia (AML) cell lines and primary AML cells in vitro were evaluated by co-culture experiments, degranulation experiments and cytokine releasing assay. Results: ① A hybridoma cell line 6E11 stably secreting anti-human CD123 antibody was developed and its variable region sequences were obtained. ② The 6E11 mAb has high affinity for CD123 protein (Kd value: 2.1 nmol/L) . The 6E11 mAb specifically recognizes CD123(+) cell line THP-1 cells and does not respond to CD123(-) cell line Jurkat cells. ③ 6E11 CAR-T cells were successfully generated with a CAR expression rate higher than 60%. ④ 6E11 CAR-T cells could specifically kill CD123(+) MV4-11 cell line but had no killing effect on the CD123(-) K562 cell line. Compared with vector-T cells, 6E11 CAR-T cells have higher killing rate to MV4-11 cells[ (98.60±1.20) %vs (20.28±6.74) %, P<0.001]. ⑤ MV4-11 cells activated 6E11 CAR-T cells significantly but not Vector-T cells[ (26.33±3.30) %vs (1.17±0.06) %, P<0.001]. ⑥ 6E11 CAR-T cells released more cytokines than vector-T cells when co-cultured with MV4-11[IL-2: (92.90±1.51) pg/ml vs (6.05±3.41) pg/ml, P<0.001; TNF-α: (1 407.20±91.95) pg/ml vs (7.86±0.85) pg/ml, P<0.001; IFN-γ: (5 614.60±170.17) pg/ml vs (8.42±2.70) pg/ml, P<0.001]. The IFN-γ, IL-2 and TNF-α in the 6E11 CAR-T group were similar to those in the Vector-T group when co-cultured with K562. ⑦ 6E11 CAR-T cells could be activated by bone marrow mononuclear cells (BMMNC) derived from CD123(+) AML patients and effectively kill these BMMNC cells from CD123(+) AML patients. Conclusion: 6E11 hybridoma cell line can stably secrete highly specific monoclonal antibodies against human CD123, which can be used to detect the expression of human CD123. It can also be used to target human CD123 protein in tumor immunotherapy. CD123 CAR-T cells with 6E11 Ig variable region sequence have specific anti-leukemic activity in vitro, which may provide a new option for further clinical research of AML. 目的: 构建一种新的靶向CD123的嵌合抗原受体T细胞(CAR-T细胞),为CD123阳性白血病的免疫治疗提供实验参考。 方法: 通过单克隆筛选技术获得能稳定分泌CD123抗体的杂交瘤细胞株6E11,将杂交瘤细胞扩增后腹腔注射至Balb/c小鼠腹腔内,收集腹水并处理、纯化得到单克隆抗体,测定抗体效价并对其特异性进行验证;RT-PCR法获得轻链和重链可变区序列,并以此为基础利用分子克隆技术构建一种新的靶向CD123嵌合抗原受体,包装病毒后感染T细胞制备CD123 CAR-T细胞,通过功能实验初步探讨6E11 CAR-T细胞体外抗白血病的能力。 结果: ①获得1株稳定分泌抗人CD123抗体的杂交瘤细胞株6E11并获得其可变区序列。②6E11单克隆抗体对CD123蛋白亲和性高,解离常数(K(d)值)为2.10 nmol/L,特异性识别CD123阳性细胞且与CD123阴性细胞无交叉反应。③成功构建了CD123 CAR慢病毒载体,感染T细胞后获得了靶向CD123的CAR-T细胞(6E11 CAR-T),感染效率大于60%。④6E11 CAR-T能明显杀伤CD123阳性靶细胞MV4-11,效靶比1∶1时6E11 CAR-T细胞对MV4-11细胞的杀伤比例明显高于Vecor-T细胞[(98.60±1.20)%对(20.28±6.74)%,P<0.001],但对CD123阴性靶细胞K562没有明显杀伤作用。⑤MV4-11细胞可以显著激活6E11 CAR-T,但对Vecor-T细胞无明显激活作用[(26.33±3.30)%对(1.17±0.06)%,P<0.001]。⑥6E11 CAR-T与MV4-11细胞共培养上清中细胞因子水平均显著高于Vecor-T组[IL-2:(92.90±1.51)pg/ml对(6.05±3.41)pg/ml,P<0.001;TNF-α:(1 407.20±91.95)pg/ml对(7.86±0.85)pg/ml,P<0.001;IFN-γ:(5 614.60±170.17)pg/ml对(8.42±2.70)pg/ml,P<0.001],但与K562细胞共培养后,两组各细胞因子水平差异无统计学意义。⑦6E11 CAR-T在与CD123阳性急性髓系白血病(AML)原代细胞共培养过程中被显著激活,且能有效杀伤原代AML细胞。 结论: 杂交瘤细胞株6E11能稳定分泌高效特异的抗人CD123单克隆抗体,可用于检测表达人CD123的细胞,也能应用在靶向人CD123蛋白的肿瘤免疫治疗中,以6E11 Ig可变区序列为抗原识别区的CD123 CAR-T细胞,具有明确的体外抗白血病活性,为进一步的临床研究奠定了基础。.
引用
- Wang ZZ, Lu Y, Xu YX, et al. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32311887. doi:10.3760/cma.j.issn.0253-2727.2020.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。